Last updated: March 2, 2026
What is the Drug and Its Indication?
NDC 60687-0381 refers to Strensiq (asfotase alfa), approved by the U.S. Food and Drug Administration (FDA) in 2015. It is used to treat hypophosphatasia (HPP), a rare genetic disorder affecting bone mineralization. Asfotase alfa is a recombinant human enzyme replacement therapy designed to improve skeletal mineralization in affected patients.
Market Size and Patient Population
Prevalence of Hypophosphatasia
- Estimated prevalence ranges from 1 in 100,000 to 1 in 300,000.
- Neonatal and infantile forms account for roughly 10-20% of cases.
- Approximate total diagnosed cases in the U.S. remain under 1,000 patients yearly.
Market Estimate Based on Patient Population
| Population Estimate |
U.S. Patients |
Global Patients |
Source |
| Conservative estimate |
500 |
2,000 |
[1] |
| Higher estimate |
1,000 |
4,000 |
[2] |
- The small patient count restricts the market size, but high unmet medical need supports sustained demand.
Market Dynamics
- The drug is primarily awarded to specialized providers due to treatment complexity.
- The pandemic has slightly delayed diagnosis, but awareness campaigns have increased early detection.
- Limited alternative therapies exist, positioning asfotase alfa as the standard of care.
Commercial Launch and Market Penetration
Earlier Market Entry
- Launched in 2015 by Alexion Pharmaceuticals, now part of AstraZeneca.
- Achieved rapid formulary inclusion in major U.S. payers due to orphan status and high unmet need.
Prescription Trends
- Year-over-year demand growth remains steady at approximately 5-8%.
- As of 2022, estimated 600-800 patients on therapy in the U.S.
- Reimbursement policies are generally favorable but have variability across payers.
Pricing Strategy and Cost Analysis
Current Price Point
- The wholesale acquisition cost (WAC) for asfotase alfa is approximately $460,000 to $470,000 per patient annually (per 2018-2022 reports).
- Actual net prices are often lower due to rebates and discounts, but median list prices remain close to published WAC.
Price Factors
- High development costs for rare disease drugs justify premium pricing.
- Manufacturing complexity due to enzyme production drives costs.
- Payer negotiations and patient assistance programs influence net revenue.
Price Comparisons
| Drug |
Indication |
List Price (Annual) |
Market Position |
| Asfotase alfa |
Hypophosphatasia |
~$460,000 |
Orphan therapy, high cure potential |
| Comparators |
None (no direct competitors) |
N/A |
Monotherapy for HPP |
Price Projections
- Expectations for the next 3-5 years suggest stable pricing, considering the lack of alternative treatments.
- Due to inflation in manufacturing or improvements in production efficiency, minor reductions in net prices could occur.
- Policy shifts toward value-based pricing might pressure list prices slightly downward, especially in Europe.
Revenue Projections and Market Outlook
Revenue Estimates (U.S. Market)
| Year |
Patients (Estimated) |
Revenue Range |
Assumptions |
| 2023 |
800 |
$368 million |
Maintaining current price levels, steady demand |
| 2024 |
850 |
$391 million |
Slight patient growth, price stability |
| 2025 |
900 |
$414 million |
Market expansion continues |
Key Drivers
- Increasing awareness leading to earlier diagnosis
- Expansion into pediatric and adult populations
- International market growth, particularly in Europe and Asia
Risks to Market and Pricing
- Entry of biosimilar alternatives could reduce list prices.
- Regulatory changes may influence reimbursement policies.
- Production breakthroughs reducing costs may impact pricing strategies.
Regulatory and Policy Considerations
- Orphan drug designation provides market exclusivity until 2030.
- Price negotiations on a national level, especially in Europe, could influence future list prices.
- The U.S. Inflation Reduction Act might target high-cost drugs for value-based reforms.
Summary of Key Data
| Data Point |
Details |
| Launch Year |
2015 |
| Annual List Price |
~$460,000 |
| Estimated U.S. Patients |
600-800 |
| Market Penetration |
Nearly saturated among eligible patients |
| Revenue Projection (2023) |
~$370 million |
| Market Exclusivity |
Until 2030 (pending patents/exclusivities) |
Key Takeaways
- NDC 60687-0381 (asfotase alfa) remains the primary treatment for hypophosphatasia, with a small but steady patient base.
- The drug's high price reflects orphan status, manufacturing costs, and lack of alternatives.
- Market revenue in the U.S. is projected to stay around $370 million for 2023, with minor growth expected.
- Biosimilar competition and policy shifts could influence pricing in coming years.
- International expansion offers additional revenue growth potential.
FAQs
Q1: How likely is biosimilar entry for asfotase alfa?
Biosimilar development is unlikely before 2030 due to patent protections and manufacturing complexity. However, competitors could enter market post-exclusivity.
Q2: What are the key factors influencing pricing negotiations?
Reimbursement policies, patient access programs, and payer cost-effectiveness assessments influence net prices.
Q3: How does the small patient population affect market sustainability?
Limited patient numbers constrain total revenue but high per-patient pricing sustains profitability.
Q4: What potential growth opportunities exist outside the U.S.?
Europe, Canada, and select Asian markets present expansion prospects, albeit with pricing and reimbursement challenges.
Q5: How might policy reforms impact the drug’s pricing?
Price controls, value-based reimbursement models, and transparency initiatives could pressure list prices downward over time.
Citations
[1] Coss, M. P., et al. (2018). Epidemiology and clinical features of hypophosphatasia. Orphanet Journal of Rare Diseases, 13(1), 42.
[2] Whyte, M. P., et al. (2020). Hypophosphatasia: Pathophysiology, diagnosis and management. Bone, 137, 115417.
